Current practices and evaluation of screening solid organ donors for West Nile virus

Transplant Infectious Disease

Volumn 14, Issue 3, 2012, Pages 268-277

  Nett, R J ^a   Kuehnert, M J ^b   Ison, M G ^c   Orlowski, J P ^d   Fischer, M ^a   Staples, J E ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Center for Donation and Transplant   (United States)

Author keywords

Donor screening; Evaluation; Nucleic acid amplification techniques; Organ transplantation; West Nile virus

Indexed keywords

ADULT; ARTICLE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DEATH; DISEASE SEVERITY; EVALUATION; FALSE POSITIVE RESULT; FEMALE; FLAVIVIRUS INFECTION; HIGH RISK PATIENT; HUMAN; INSECT BITE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MOSQUITO; NEUROLOGIC DISEASE; NONHUMAN; NUCLEIC ACID AMPLIFICATION; ORGAN DONOR; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCREENING; UNITED STATES; WEST NILE FLAVIVIRUS;

ADOLESCENT; ADULT; DONOR SELECTION; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NUCLEIC ACID AMPLIFICATION TECHNIQUES; ORGAN TRANSPLANTATION; TISSUE AND ORGAN HARVESTING; TISSUE DONORS; UNITED STATES; WEST NILE FEVER; WEST NILE VIRUS; YOUNG ADULT;

EID: 84862188557     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2012.00743.x     Document Type: Article

References (46)

1. Campbell GL, Marfin AA, Lanciotti RS, Gubler DJ. West Nile virus. Lancet Infect Dis 2002; 2: 519-529.
2. Lindsey NP, Staples JE, Lehman JA, Fischer M; Centers for Disease Control and Prevention. Surveillance for human West Nile virus disease - United States, 1999-2008. MMWR Surveill Summ 2010; 59: 1-17.
3. Petersen LR, Marfin AA. West Nile virus: a primer for the clinician. Ann Intern Med 2002; 137: 173-179.
4. Mostashari F, Bunning ML, Kitsutani PT, et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet 2001; 358: 261-264.
5. Gea-Banacloche J, Johnson RT, Bagic A, Butman JA, Murray PR, Agrawal AG. West Nile virus: pathogenesis and therapeutic options. Ann Intern Med 2004; 140: 545-553.
6. Penn RG, Guarner J, Sejvar JJ, et al. Persistent neuroinvasive West Nile virus infection in an immunocompromised patient. Clin Infect Dis 2006; 42: 680-683.
7. Davis LE, DeBiasi R, Goade DE, et al. West Nile virus neuroinvasive disease. Ann Neurol 2006; 60: 286-300.
8. Pealer LN, Marfin AA, Petersen LR, et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003; 349: 1236-1245.
9. Iwamoto M, Jernigan DB, Guasch A, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003; 348: 2196-2203.
10. Centers for Disease Control and Prevention. West Nile virus infections in organ transplant recipients-New York and Pennsylvania, August-September, 2005. MMWR 2005; 54: 1021-1023.
11. Centers for Disease Control and Prevention. West Nile virus transmission via organ transplantation and blood transfusion - Louisiana, 2008. MMWR 2009; 58: 1263-1267.
12. Rhee C, Eaton EF, Concepcion W, Blackburn B. West Nile virus encephalitis acquired via liver transplantation and clinical response to intravenous immunoglobulin: case report and review of the literature. Transpl Infect Dis 2011; 16: 312-317.
13. Costa AN, Capobianchi MR, Ippolito G, et al. West Nile virus: the Italian national transplant network reaction to an alert in the north-eastern region, Italy 2011. Euro Surveill 2011; 16: pii = 19991.
14. Kiberd BA, Forward K. Screening for West Nile virus in organ transplantation: a medical decision analysis. Am J Transplant 2004; 4: 1296-1301.
15. Organ Procurement and Transplantation Network. National Data. Available at (accessed July 11, 2011).
16. Morelli MC, Sambri V, Grazi GL, et al. Absence of neuroinvasive disease in a liver transplant recipient who acquired West Nile virus (WNV) infection from the organ donor and who received WNV antibodies prophylactically. Clin Infect Dis 2010; 51: e34-37.
17. The Health Resources and Services Administration. A Special Announcement from HRSA Regarding West Nile Virus. Available at (accessed July 11, 2011).
18. Fischer SA, Avery RK. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant 2009; 9 (Suppl 4): S7-18.
19. Orlowski J, Alexander C, Ison M, Rosendale J, Chabalewski F. Nucleic Acid Testing (NAT) for HIV, HBV, and HCV: Current Practices of 58 US Organ Procurement Organizations (OPOs). Boston, MA: American Transplant Congress, 2009.
20. Ison MG, Pruett T, Teperman L, et al. Donor Serological Screening: Current Practices and Future Challenges - A Survey Reported by the OPTN/UNOS Ad Hoc Disease Transmission Advisory Committee (DTAC). Boston, MA: American Transplant Congress, 2009.
21. Tilley PA, Fox JD, Jayaraman GC, Preiksaitis JK. Nucleic acid testing for West Nile virus RNA in plasma enhances rapid diagnosis of acute infection in symptomatic patients. J Infect Dis 2006; 193: 1361-1364.
22. Food and Drug Administration. Procleix WNV Assay: Summary Basis of Approval. Available at (accessed July 11, 2011).
23. Food and Drug Administration. Approval Letter - COBAS TaqScreen West Nile Virus Test. Available at (accessed July 11, 2011).
24. Food and Drug Administration. Approval Letter - Procleix Ultrio WNV Assay. Available at (accessed July 11, 2011).
25. Zhang W, Wu J, Li Y, Li F, Njoo H. Rapid and accurate in vitro assays for detection of West Nile virus in blood and tissues. Transfus Med Rev 2009; 23: 146-154.
26. ® West Nile virus assay on semi-automated and automated systems. J Med Virol 2007; 79: 1422-1430.
27. Chinchilla C, Siriban J, Brucal D, et al. Real-time Screening for West Nile Virus (WNV) of Organ Donors. San Diego, CA: American Transplant Congress, 2010.
28. Planitzer CB, Modrof J, Yu MY, Kreil TR. West Nile virus infection in plasma of blood and plasma donors, United States. Emerg Infect Dis 2009; 15: 1668-1670.
29. Barber LM, Schleier JJ 3rd, Peterson RK. Economic cost analysis of West Nile virus outbreak, Sacramento County, California, USA, 2005. Emerg Infect Dis 2010; 16: 480-486.
30. Orton SL, Stramer SL, Dodd RY. Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors. Transfusion 2006; 46: 272-277.
31. Tilley PAG, Fox JD, Lee B, Chui L, Preiksaitis J. Screening of organ and tissue donors for West Nile virus by nucleic acid amplification - a three year experience in Alberta. Am J Transplant 2008; 8: 2119-2125.
32. Schaffner A. Pretransplant evaluation for infections in donors and recipients of solid organs. Clin Infect Dis 2001; 33 (Suppl 1): S9-14.
33. AABB (American Association of Blood Banks). West Nile Virus Biovigilance Network Frequently Asked Questions. Available at (accessed October 14, 2011).
34. Roehrig JT, Nash D, Maldin B, et al. Persistence of virus-reactive serum immunoglobulin M antibody in confirmed West Nile virus encephalitis cases. Emerg Infect Dis 2003; 9: 376-379.
35. Hayes EB, Sejvar JJ, Zaki SR, et al. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis 2005; 11: 1174-1179.
36. Kleinman SH, Williams JD, Robertson G, et al. West Nile virus testing experience in 2007: evaluation of different criteria for triggering individual-donation nucleic acid testing. Transfusion 2009; 49: 1160-1170.
37. Murray K, Walker C, Herrington E, et al. Persistent infection with West Nile virus years after initial infection. J Infect Dis 2010; 201: 2-4.
38. Freifeld AG, Meza J, Schweitzer B, Shafer L, Kalil AC, Sambol AR. Seroprevalence of West Nile virus infection in solid organ transplant recipients. Transpl Infect Dis 2009; 12: 120-126.
39. Kleinschmidt-DeMasters BK, Marder BA, Levi ME, et al. Naturally acquired West Nile virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features. Arch Neurol 2004; 61: 1210-1220.
40. Kumar D, Drebot MA, Wong SJ, et al. A seroprevalence study of West Nile virus infection in solid organ transplant recipients. Am J Transplant 2004; 4: 1883-1888.
41. Humar A. Screening for West Nile virus: more uncertainty. Am J Transplant 2004; 4: 1217-1218.
42. Siddharthan V, Wang H, Motter NE, et al. Persistent West Nile virus associated with a neurological sequela in hamsters identified by motor unit number estimation. J Virol 2009; 83: 4251-4261.
43. Tesh RB, Siirin M, Guzman H, et al. Persistent West Nile virus infection in the golden hamster: studies on its mechanism and possible implications for other flavivirus infections. J Infect Dis 2005; 192: 287-295.
44. Tonry JH, Xiao SY, Siirin M, Chen H, da Rosa AP, Tesh RB. Persistent shedding of West Nile virus in urine of experimentally infected hamsters. Am J Trop Med Hyg 2005; 72: 320-324.
45. Gibney KB, Lanciotti RS, Sejvar JJ, et al. West Nile virus RNA not detected in urine of 40 people tested 6 years after acute West Nile virus disease. J Infect Dis 2011; 203: 344-347.
46. Baty SA, Gibney KB, Staples JE, et al. Evaluation for West Nile virus (WNV) RNA in urine of patients within 5 months of WNV infection. J Infect Dis 2012; 205 (9): 1476-1477.